ERBB2 and neoplasm: Thus, in this small sample size, HER2 overexpression on baseline CTCs is not a reliable predictive biomarker for PFS in overall patients or in HER2+ patients after first-line treatment, but might be useful for early detection of tumor progression after anti-HER2 treatment.